BPC-157

If you have an active malignancy or recent cancer history: BPC-157 promotes angiogenesis — the formation of new blood vessels. This is central to how it accelerates healing. It is also central to how tumors grow and metastasize. No human cancer case has been linked to BPC-157, but the biological mechanism is real, and zero studies have evaluated this risk in cancer patients. If you have an active cancer, are in remission, or have a strong family history of cancer, this conversation belongs with your oncologist — not your peptide provider, not a Reddit thread.

If you are on anticoagulants (blood thinners): BPC-157 interacts with the nitric oxide system and has demonstrated effects on blood vessel formation and platelet function in animal models. If you are on warfarin, heparin, direct oral anticoagulants (DOACs like apixaban or rivarelbano), or even daily aspirin therapy, the interaction profile is unstudied in humans. Your prescribing physician for the anticoagulant must be in the loop.

If you are on blood pressure medications: BPC-157’s nitric oxide pathway interactions could theoretically affect blood pressure regulation. If you’re on antihypertensives — particularly ACE inhibitors, ARBs, or calcium channel blockers — your provider needs to monitor for unexpected changes in blood pressure during treatment.

If you are pregnant or breastfeeding: No safety data exists. This is not a situation where “probably fine” is an acceptable standard.

If you have a hormone-sensitive condition: This includes estrogen-receptor-positive breast cancer history, endometriosis, uterine fibroids, or other conditions where angiogenesis or growth factor modulation could have downstream hormonal effects. The interaction is theoretical but biologically plausible.

If you are a competitive athlete in a tested league: BPC-157 is prohibited by WADA and most major US professional sports leagues. A positive test can end your season or career. “My provider prescribed it” is not a defense under anti-doping rules.

If you are self-sourcing from unregulated vendors: BPC-157 is a Category 2 peptide expected to return to Category 1 under the announced reclassification, but as of April 2026, no formal FDA action has been taken. If you’re buying BPC-157 from a “research peptide” website, you have no assurance of purity, sterility, or accurate dosing. Independent testing has found contamination, mislabeling, and in some cases, no active compound at all. The injury you’re trying to heal is not worth a systemic infection from a contaminated vial.

The general principle: BPC-157 has a promising preclinical profile and a growing body of practitioner-reported outcomes. It is not a proven therapeutic with established safety boundaries. Fewer than 30 humans have been studied in published trials, and the longest follow-up is 12 months. If you’re using it, you are accepting a level of uncertainty — and the minimum responsible behavior is to do so with a licensed provider who knows your full medical history, including every medication and supplement you’re taking.